Plaintiffs attorneys suing over the breast cancer drug Taxotere want a federal judge to sanction defendant Sanofi-Aventis U.S. LLC for filing a motion filled with “unfounded accusations” that are “indecent and vexatious” in an attempt to get information on outside funding for the litigation.

The motion, they wrote in a Tuesday filing, is “an unfounded and unseemly attempt to smear both breast cancer survivors” and their lawyers “based entirely on innuendo that is pure McCarthyism.” “Sanofi has not even a scintilla of evidence that plaintiffs' attorneys are giving up control of their clients' cases to anyone; they are not,” wrote co-lead plaintiffs attorneys Christopher Coffin, a partner at Pendley Baudin & Coffin in New Orleans, and Karen Barth Menzies, a Los Angeles partner at Girard Gibbs.

The pushback comes amid a growing number of requests for transparency in third-party financing of mass tort litigation. Similar requests have been made in cases involving blood thinner Xarelto and Johnson & Johnson's baby powder.